Efficacy and Safety of Janagliflozin as Add-on Therapy to Metformin in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.
Diabetes, Obesity and Metabolism(2022)
摘要
Janagliflozin 25 mg or 50 mg once-daily added to metformin therapy significantly improved glycemic control, reduced body weight and SBP, improved HDL-C and insulin sensitivity, and was generally well-tolerated by Chinese T2DM patients who had poor glycemic control with metformin monotherapy. This article is protected by copyright. All rights reserved.
更多查看译文
关键词
add-on therapy,janagliflozin,metformin,renal sodium-glucose cotransporter-2 inhibitor,type 2 diabetes mellitus
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要